Evidence map›Paper›PMID 29977864›Full record

ReviewFrontiers in oncology2018

Machine Learning and Radiogenomics: Lessons Learned and Future Directions.

John Kang, Tiziana Rancati, Sangkyu Lee, Jung Hun Oh, Sarah L Kerns, Jacob G Scott, Russell Schwartz, Seyoung Kim, Barry S Rosenstein

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Gender Medicine in Clinical Radiology Practice.Journal of personalized medicine · 2023
    Review
  13. Artificial intelligence applications in pediatric oncology diagnosis.Exploration of targeted anti-tumor therapy · 2023
    Review
  14. Review
  15. Prostate Cancer Radiogenomics-From Imaging to Molecular Characterization.International journal of molecular sciences · 2021
    Review
  16. Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2021
    Article
  17. Article
  18. Review
  19. Article
  20. Radiogenomics in Interventional Oncology.Current oncology reports · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

John KangDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, United States.
Tiziana RancatiProstate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Sangkyu LeeDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Jung Hun OhDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Sarah L KernsDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, United States.
Jacob G ScottDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, United States.
Russell SchwartzComputational Biology Department, Carnegie Mellon School of Computer Science, Pittsburgh, PA, United States.
Seyoung KimComputational Biology Department, Carnegie Mellon School of Computer Science, Pittsburgh, PA, United States.
Barry S RosensteinDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Genome-Wide Study to Identify SNPs and CNPs Associated with Radiation InjuryR01CA134444 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI OSTRER, HARRY, ROSENSTEIN, BARRY S · 2009 to 2012
$2.3M
Risk Prediction for Development of Adverse Effects FOllowing Radiotherapy for Prostate CancerK07CA187546 · NCI · UNIVERSITY OF ROCHESTER · PI KERNS, SARAH L. · 2015 to 2019
$649k
DECONVOLUTION OF CLONAL HETEROGENEITY FROM BULK AND SINGLE-CELL VARIATION DATAR21CA216452 · NCI · CARNEGIE-MELLON UNIVERSITY · PI SCHWARTZ, RUSSELL S · 2017 to 2018
$342k
CLC NIH HHS HHSN261201700033CNCI NIH HHS HHSN261201500043CNCI NIH HHS K07 CA187546NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA134444NCI NIH HHS R21 CA216452
6 · The paper itself

Abstract

Due to the rapid increase in the availability of patient data, there is significant interest in precision medicine that could facilitate the development of a personalized treatment plan for each patient on an individual basis. Radiation oncology is particularly suited for predictive machine learning (ML) models due to the enormous amount of diagnostic data used as input and therapeutic data generated as output. An emerging field in precision radiation oncology that can take advantage of ML approaches is radiogenomics, which is the study of the impact of genomic variations on the sensitivity of normal and tumor tissue to radiation. Currently, patients undergoing radiotherapy are treated using uniform dose constraints specific to the tumor and surrounding normal tissues. This is suboptimal in many ways. First, the dose that can be delivered to the target volume may be insufficient for control but is constrained by the surrounding normal tissue, as dose escalation can lead to significant morbidity and rare. Second, two patients with nearly identical dose distributions can have substantially different acute and late toxicities, resulting in lengthy treatment breaks and suboptimal control, or chronic morbidities leading to poor quality of life. Despite significant advances in radiogenomics, the magnitude of the genetic contribution to radiation response far exceeds our current understanding of individual risk variants. In the field of genomics, ML methods are being used to extract harder-to-detect knowledge, but these methods have yet to fully penetrate radiogenomics. Hence, the goal of this publication is to provide an overview of ML as it applies to radiogenomics. We begin with a brief history of radiogenomics and its relationship to precision medicine. We then introduce ML and compare it to statistical hypothesis testing to reflect on shared lessons and to avoid common pitfalls. Current ML approaches to genome-wide association studies are examined. The application of ML specifically to radiogenomics is next presented. We end with important lessons for the proper integration of ML into radiogenomics.

Indexed as

big datacomputational genomicsmachine learning in radiation oncologyprecision oncologypredictive modelingradiation oncologystatistical genetics and genomics

Identifiers

PMID29977864
PMCPMC6021505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.